Butterfly Network (BFLY) CEO says Sam Altman is now starting his own neuralink and chose Butterfly

Episodes of this sort have tended to move thinly traded names sharply in the short term, with the durability of the move hinging on whether a contract, purchase order, or equity investment follows; absent paper, prior instances have usually retraced. The distinction worth drawing is between a supplier relationship and a strategic partnership: the former implies modest, revocable revenue, the latter something closer to validation, and the headline as it stands supports neither reading firmly. The actor context matters too: ventures launched by high-profile founders in already-contested technical fields have a mixed record of reaching commercial scale, and the claimed field here is one where established players operate under heavy regulatory and clinical constraints. Worth watching next is whether the company files anything substantive, whether the named founder's entity confirms the relationship, and whether any revenue quantification appears in the next reported period. Until then this is single-source commentary from an interested party.